A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other. The BCG (Bacille Calmette-Guérin) vaccine, created in 1921, remains the sole TB vaccine. While it is 40% to 80% effective in young children, its […] The post The path to a better Tuberculosis vaccine runs through Montana appeared first on Daily Montanan.
India-based vaccine maker Bharat Biotech and Spanish biopharma player Biofabri commence the clinical trials of the world's first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, MTBVAC, to evaluate its safety, immunogenicity and efficacy.
A senior officer from health department requesting anonymity, said, that despite the widespread use of the BCG vaccine, there is still considerable debate on its effectiveness in preventing TB and the duration of immunity post-vaccination